Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Hasılat
9
9
10
9
9
13
Hasılat Artışı (YoY)
-10%
-10%
11%
0%
-31%
44%
Satınalma Maliyeti
7
7
7
5
8
7
Brüt Kâr
2
1
2
3
1
5
Satış, Genel ve İdari
6
7
7
8
7
8
Araştırma ve Geliştirme
1
1
1
2
2
2
İşletme Giderleri
8
8
8
10
10
10
Diğer Finansman Gelirleri (Giderleri)
0
0
0
0
0
0
Kâr Öncesi Gelir
-15
-18
-11
-11
-16
-10
Kira Vergisi Gideri
--
--
--
--
--
0
Net Kâr
-14
-17
-11
-11
-16
-9
Net Income Growth
Kâr Artışı
0%
55%
0%
-31%
78%
-77%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
4.02
2.36
0.55
0.26
0.14
0.06
Hisse Değişimi (Yıllık Üst Üste)
222%
331%
112%
86%
133%
50%
EPS (Diluted)
-3.66
-7.59
-20.49
-43.76
-116.78
-158.33
EPS Artışı
-68%
-63%
-53%
-63%
-26%
-84%
Öz sermaye akışı
-4
-5
-7
-6
-14
-3
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
22.22%
11.11%
20%
33.33%
11.11%
38.46%
Faaliyet Kâr Marjı
-66.66%
-66.66%
-60%
-77.77%
-88.88%
-30.76%
Kâr Marjı
-155.55%
-188.88%
-110%
-122.22%
-177.77%
-69.23%
Özsermaye Karlılık Oranı
-44.44%
-55.55%
-70%
-66.66%
-155.55%
-23.07%
EBITDA
-5
-5
-6
-7
-8
-4
EBITDA Marjinali
-55.55%
-55.55%
-60%
-77.77%
-88.88%
-30.76%
D&A EBITDA için
1
1
0
0
0
0
Faaliyet Kârı
-6
-6
-6
-7
-8
-4
Faaliyet Kâr Marjı
-66.66%
-66.66%
-60%
-77.77%
-88.88%
-30.76%
Verilen Vergi Oranı
--
--
--
--
--
0%
Önemli İstatistikler
Önceki Kapanış
$0.0001
Açılış fiyatı
$0
Günün Aralığı
$0 - $0
52 haftalık aralık
$0 - $0.0003
İşlem hacmi
331
Ort.Hacim
396
EPS (TTM)
-5.00
Dividend yield
--
Piyasa Değeri
$1.5K
THMO nedir?
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. The company is headquartered in Rancho Cordova, California and currently employs 25 full-time employees. The firm provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The firm markets and sells its medical device products through independent distributors.